Adagene Unveils Upcoming Poster Presentations
Adagene Inc. (Nasdaq: ADAG), a pioneering company in the realm of antibody-based therapies, is set to share groundbreaking insights at the SITC 39th Annual Meeting. This prestigious event will convene in Houston, showcasing the latest advancements in cancer immunotherapies.
Details of the Presentations
Among the highlights, Adagene is excited to present two significant posters focused on its promising therapy, ADG126, also known as Muzastotug. Both presentations will delve into its efficacy and therapeutic index when used as a monotherapy and in combination with anti-PD-1 therapy.
Deciphering Clinical Therapeutic Index
This presentation explores the improved clinical therapeutic index of Muzastotug compared to its unmasked counterpart, ADG116. Scheduled for November 9, attendees can participate during the Lunch & Poster Viewing session from 12:15 PM to 1:45 PM CST, followed by a poster reception that evening from 7:10 PM to 8:30 PM CST at the George R. Brown Convention Center.
Phase 1b/2 Multicenter Study
The second presentation highlights the Phase 1b/2 multicenter dose escalation and expansion study involving Muzastotug in combination with Pembrolizumab, particularly targeting advanced and metastatic colorectal cancers. This session also takes place on November 9, promising to shine a light on the therapeutic advancements in colorectal cancer.
About Adagene Inc.
Adagene is at the forefront of transforming cancer treatment through its innovative antibody-based therapies. Utilizing advanced computational biology and artificial intelligence, the company designs cutting-edge antibodies aimed at addressing unmet needs in oncology. Their SAFEbody® precision masking technology is revolutionary, offering a novel approach by shielding the binding domain of biologics to enhance safety and efficacy.
Key Highlights of Adagene's Development Strategy
With a strong focus on the tumor microenvironment, Adagene’s lead clinical program, ADG126 (Muzastotug), targets CTLA-4 specifically in regulatory T cells, thereby maximizing the potential for patient benefit while minimizing potential side effects. Clinical studies are pivotal in reaffirming the wide-reaching applications of their SAFEbody platform, which is suitable for various therapeutic modalities, including Fc empowered antibodies.
Engagement and Communication
For those interested in the latest updates and information about Adagene’s clinical programs, more resources are available on their official website. Their commitment to transparency ensures accessibility to the latest research findings and collaborations, contributing to their mission to innovate cancer therapies.
Adagene continues to expand its strategic partnerships, further solidifying its position in the biotechnology sector as a key player dedicated to advancing cancer treatments globally. For regular updates and insights, stakeholders can follow the company's social media channels, including WeChat, LinkedIn, and Twitter.
Frequently Asked Questions
What is the significance of the presentations at SITC?
The presentations highlight Adagene's innovative approaches to cancer treatment and illustrate the clinical potential of their therapy ADG126.
When will the poster presentations take place?
The presentations are scheduled for November 9, 2024, during the SITC Annual Meeting in Houston.
What is ADG126?
ADG126, also known as Muzastotug, is a masked anti-CTLA-4 SAFEbody designed to improve safety and efficacy in cancer therapy.
How does Adagene's technology enhance therapeutic outcomes?
The SAFEbody technology provides precision masking, which minimizes off-target toxicity and enhances tumor-specific targeting.
Where can I find more information about Adagene?
More details can be found on Adagene's official website, along with their latest news and clinical updates.
